Activin A Is Anti-Lymphangiogenic in a Melanoma Mouse Model  by Heinz, Magdalena et al.
Activin A Is Anti-Lymphangiogenic in a Melanoma
Mouse Model
Magdalena Heinz1, Heide Leb Niederleithner1, Emmi Puujalka1, Ana Soler-Cardona1,2, Michael Grusch3,
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Melanoma spreads primarily to the sentinel lymph nodes, and its risk correlates with lymphangiogenesis, which
is mainly driven by vascular endothelial growth factor (VEGF)-C. However, anti-lymphangiogenic factors are
poorly characterized. We have shown in a melanoma model that Wnt1 reduces lymphangiogenesis by reducing
VEGF-C expression. Screening this model for additional potentially anti-lymphangiogenic factors identified
increased activin A expression and reduced expression of the antagonist, follistatin (FST), in Wnt1þ cells. Activin
A is known to reduce blood vessel formation, but the effects on lymphangiogenesis are unknown. Here we show
that human primary melanoma expresses significantly higher levels of activin A and lower levels of FST compared
with nevi and melanoma metastasis. Using our mouse model with melanoma cells overexpressing Wnt1, FST,
Wnt1/FST, or the inhibin bA subunit (INHBA, resulting in activin A expression), we found both activin A and Wnt1
to reduce lymphangiogenesis. Whereas Wnt1 also reduced metastasis, this was not seen with activin A. In vitro,
activin A phosphorylated SMAD2 in both melanoma and lymphatic endothelium but, although it reduced
sprouting of lymphatic endothelium, it enhanced the migration of melanoma cells. In conclusion, activin A is an
anti-lymphangiogenic factor, but because of its pleiotropic effects on cell mobility it appears not suitable as a
pharmacological target.
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INTRODUCTION
Activin A is a member of the transforming growth factors (TGF)
b-superfamily and consists of two inhibin bA subunits. Four
b-subunit human genes are known, INHBA (bA), INHBB (bB),
INHBC (bC), and INHBE (bE), but only the bA/bA (activin A),
bB/bB (activin B), and bA/bB (activin AB) dimers have been
studied in detail. Heterodimerization of the activin b-subunits
with the inhibin a-subunit results in inhibin A (a/bA) and
inhibin B (a/bB).
Activin A binds to two proteins of a transmembrane serine/
threonine kinase receptor known as activin type II receptor
type IIA (ActRIIA or ACVR2) and type IIB (ActRIIB or
ACVR2B), respectively, which each then bind to one protein
of a type I receptor resulting in a tetramer complex. Two type I
receptors are known to be involved in activin signaling. ALK4,
also referred to as activin type IB receptor (ActRIB or
ACVR1B), is the main type I receptor for activin A, whereas
ALK7, also known as activin type IC receptor (ACVR1C), is
involved in activin B and activin AB signaling (Lotinun et al.,
2012).
Signal transduction continues via the phosphorylation of
SMAD 2/3, which leads to binding of the signal transducer
SMAD4. This complex translocates into the nucleus and
promotes gene transcription. Activin A is involved in multiple
cellular processes such as proliferation, metabolism, differen-
tiation, immune responses, and apoptosis. Its effects are
pleiotropic, and tissue type– and context dependent (Deli
et al., 2008; Antsiferova and Werner, 2012). Follistatin (FST) is
an inhibitor of activin A signaling; it binds to activin A with
high affinity and blocks the receptor–ligand interaction (Deli
et al., 2008). Thus, activin A activity depends on the ratio of
activin A to FST.
Endothelial cells express activin receptors ActRI and ActRII
and respond to activin A by reduced proliferation in vitro and
reduced angiogenesis in a CAM assay (McCarthy and Bicknell,
1993; Breit et al., 2000). Moreover, activin A is antiangiogenic
in several tumor models (Panopoulou et al., 2005; Schramm
et al., 2005; Krneta et al., 2006; Kaneda et al., 2011).
However, activin A may also indirectly act proangiogenic
through the induction of vascular endothelial growth factor
(VEGF)-A expression in, e.g., hepatocellular carcinoma
(Wagner et al., 2004) or in corneal epithelial cells (Poulaki
et al., 2004). Activin A also has a two-edged role in cancer: in
breast cancer and hepatoma cells, activin A inhibits cell
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growth and promotes apoptosis (Burdette et al., 2005), but it
increases the migration of prostate cancer cells (Kang et al.,
2009) and keratinocytes (Zhang et al., 2005). It is also
associated with tumor progression and poor prognosis in
oral squamous cell carcinoma (Chang et al., 2010).
Melanoma cells in culture express activin A and activin
receptors and respond to activin A with reduced growth and
induced apoptosis, which is antagonized by FST (Stove et al.,
2004). However, to the best of our knowledge, expression of
activin A in human melanoma is not characterized, and its
effect is not tested in in vivo models.
Our interest in activin A is based on our recent study
demonstrating that Wnt1 negatively regulates lymphangiogen-
esis by reducing melanoma-derived VEGF-C expression result-
ing in reduced metastasis (Niederleithner et al., 2012). This
link between VEGF-C, lymphangiogenesis, and metastasis in
melanoma is firmly established in several experimental
models and in humans (Skobe et al., 2001; Goydos and
Gorski, 2003; Schietroma et al., 2003; Dadras et al., 2005;
Hoshida et al., 2006; Niederleithner et al., 2012; Swoboda
et al., 2012; Bracher et al., 2013). It also suggests that VEGF-C
is the master regulator of lymphangiogenesis in melanoma. To
challenge this implication and to search for additional factors
regulating lymphangiogenesis, we reanalyzed gene expression
arrays performed in our Wnt1 study and identified an incre-
ased activin A to FST ratio in Wnt1-overexpressing melanoma.
As activin A is known to negatively regulate blood vessel
formation in cancer, we tested (i) whether activin A is
expressed in human melanoma in vivo, (ii) whether it alters
melanoma growth and metastasis, (iii) whether it contributes
to Wnt1 effects, and (iv) whether activin A itself regulates
lymphangiogenesis.
RESULTS
Primary melanomas have an increased INHBA to FST ratio
compared with nevi
INHBA and FST expression was quantified by immunohisto-
chemistry in compound nevi (n¼19), primary superficial
spreading melanoma (SSM, T2a, thickness 1–2 mm, n¼ 10),
and melanoma metastasis (Mel met, n¼81). SSM had sig-
nificantly elevated INHBA/FST ratios compared with nevi and
metastasis (Figure 1a). Examples for staining of FSThigh and
INHBAlow nevi and FSTlow and INHBAhigh SSM are presented
in Figure 1b.
Activin A does not affect melanoma growth and metastasis
in vivo
Cultured A375 cells were transduced with control vectors,
Wnt1, FST, Wnt1 plus FST, and INHBA (coding for the inhibin
bA subunit). It is noteworthy that overexpression of INHBA
resulted in activin A expression only, as these cells do not
express any other inhibin subunit (Supplementary Figure 1a
online). Importantly, in contrast to Wnt1, INHBA did not
reduce VEGF-C expression compared with controls in cultured
A375 cells (Supplementary Figure 1e online).
After intradermal injection of A375 cells (overexpressing the
indicated transgenes) into the right flank of severe combined
immunodeficient mice, arising tumors had comparable growth
curves (Supplementary Figure 1f online) and were excised at
day 22. Tumors were tested for proper expression of the
respective transgenes (Figure 2). Immunohistochemistry with
anti-Lyve-1 antibodies revealed dilated lymphatic vessels
surrounding the tumors, which were invaded by melanoma
cells in all groups, except for those expressing Wnt1 (exem-
plified in Figure 3a; quantification in Figure 3b).
Sentinel lymph nodes were excised on suspicious tactile
results: Sentinel nodes of INHBA mice were found to be
positive at day 18±0 days, and all of them proved to be
positive by immunohistochemistry (exemplified in Figure 3c);
sentinel nodes of control mice were excised on day 33±17
days (93% thereof positive by immunohistochemistry); and
sentinel nodes of FST mice were excised on day 35±14.1
days (58% thereof positive). Wnt1 and Wnt/1FST mice were
sacrificed at day 70 and lymph nodes were found without
metastasis by macroscopyic evaluation as well as by immu-
nohistochemistry (Figure 3c).
Activin A decreases the numbers of peritumoral lymphatic
vessels
INHBA melanoma had significantly reduced numbers of
lymphatic vessels (similar to Wnt1) compared with controls
(Figure 4a; Po0.05), as determined in tissue sections stained
with anti-Lyve-1 antibodies. Wnt1/FST coexpression also
resulted in decreased lymphangiogenesis, indicating that
activin A did not contribute to Wnt1 effects on lymph vessels
(Figure 4a). These findings correlated with the Lyve-1 mRNA
levels determined by real-time PCR (insert Figure 4a). As
examples, immunohistochemistry for control and INHBA
tumors are shown, and the analyzed zone of 250mm
surrounding the tumor is marked. CD31-positive vessels (i.e.,
lymph and blood vessels) were counted for comparison and
revealed comparable results (Figure 4b).
Activin A increases melanoma migration but reduces lymphatic
endothelial sprout formation in vitro
To further characterize divergent in vivo effects of activin A on
melanoma and lymphatic endothelium, we first determined
their sensitivity to activin A. Both A375 cells and human
lymphatic endothelium responded to activin A by increased
SMAD2 phosphorylation (Supplementary Figure 1b and c
online). Moreover, also mouse endothelium (as given in the
in vivo model) responded to human activin A, which was
blocked by FST (Supplementary Figure 1d online). Prolifera-
tion rates of A375 or lymphatic endothelial cells (LECs) in vitro
did not differ between groups (Figure 5a). In contrast, A375
cell migration was significantly increased in A375 cells over-
expressing INHBA, reaching 98% confluence after
31±2.8 hours (P¼0.027 compared with controls), whereas
controls needed 42.5±7.7 hours, Wnt1 cells needed
36±1.4 hours, Wnt1/FST cells needed 41.5±0.7 hours, and
FST cells needed 55±2.1 hours (P¼0.016) to reach 98%
confluence (Figure 5b). To exclude that the effect of activin on
migration is an A375-specific response, three additional
human melanoma cells, VM-1, VM-30, and VM-34, were
tested (Figure 5c). Activin A induced SMAD2 phosphorylation
in all three cell lines more efficiently than TGF-b or Wnt3a (in
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our hands recombinant Wnt1 is non functional). None of the
three stimuli altered cell proliferation. Activin A induced
migration in all three cell lines compared with controls, but
most effectively in VM-34 cells.
In LECs, supernatants from INHBA-overexpressing A375
cells significantly decreased the cumulative sprout length in a
three-dimensional in vitro spheroid sprouting assay. Wnt1
inhibited sprout formation, as published previously
(Niederleithner et al., 2012), whereas FST had no effect
compared with the control (Figure 6).
DISCUSSION
Melanoma typically arises in the skin and initially shows
horizontal spreading followed by vertical invasion into the
dermis. The vertical growth and not the size of lateral
expansion correlates with the risk of metastasis to sentinel
lymph nodes. Increased risk can be observed in tumors
invading the dermis to a depth of 41 mm (Balch et al.,
2009), and even these very thin tumors induce lymphangio-
genesis. It is amply documented that the peritumoral lymph
vessel density correlates with the risk for metastasis in human
patients (Dadras et al., 2003; Shields et al., 2004; Dadras
et al., 2005; Massi et al., 2006; Shayan et al., 2012).
VEGF-C is the best-characterized lymphangiogenic factor
(Alitalo and Detmar, 2012). Human melanoma produces
VEGF-C. Other relevant lymphangiogenic factors expressed
in melanoma include, among others, VEGF-D (Achen et al.,
2001), epidermal growth factor (Bracher et al., 2013), or
fibroblast growth factor-2 (Reed et al., 1994), but the clinical
importance for lymphangiogenesis and metastasis in humans
is mainly documented for VEGF-C (Cianfarani et al., 2012).
However, very little is known about anti-lymphangiogenic
factors. Examples are factors downregulating Prox1 expre-
ssion, such as bone morphogenetic protein-9 (Yoshimatsu
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Figure 1. Human primary melanomas have an increased INHBA to follistatin ratio compared with nevi and metastasis. (a) Quantified expression of
immunohistochemistry staining for the inhibin bA subunit (INHBA) and follistatin (FST) in human nevi (n¼ 19), primary melanoma (SSM; n¼10), and metastasized
melanoma (Mel met; n¼ 81). *Po0.05. (b) Examples for immunohistochemistry stainings for FST and INHBA expression in a nevus and a primary melanoma.
Antibody binding is visualized by red color; counterstaining with hematoxylin is blue. Isotype controls for the respective antibodies are shown at the bottom;
corresponding H&E sections are shown at the right side. Bars ¼ 100mm. H&E, hematoxylin and eosin; INHBA, inhibin bA subunit; SSM, superficial spreading
melanoma.
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et al., 2013) or IL-4 and IL-13 (Sin et al., 2013). Collagen
XVIII cleavage products (Kojima et al., 2008) and the non-
collagenous C-terminal globular domain of collagen 4
(Weckmann et al., 2012) also reduce lymphangiogenesis.
Virtually nothing is known about the production of anti-
lymphangiogenic factors by melanoma itself.
We describe activin A as a anti-lymphangiogenic factor,
which is produced in melanoma in vitro and in vivo. Activin A
prevents lymphatic sprout formation in vitro and reduces
lymphangiogenesis in vivo. The herein described effects of
activin A on LECs are similar to several reports analyzing the
effects of activin A on blood vessels, where it reduced
endothelial cell tube formation in vitro and angiogenesis
in vivo (Panopoulou et al., 2005; Kaneda et al., 2011).
Importantly, activin A does not change VEGF-C expression
in our experiments, in contrast to Wnt1, which reduces
lymphangiogenesis via the inhibition of VEGF-C (VEGF-D is
not expressed in A375 cells). Moreover, activin A does not
reduce Prox1 expression in the lymphatic endothelium (data
not shown), which distinguishes its mode of action from BMP9
(Yoshimatsu et al., 2013). We have shown that LECs respond
to activin A by SMAD2 phosphorylation, but we have not yet
further characterized the downstream signaling. As activin A
reduces LEC sprouting but not LEC proliferation (data not
shown), we suggest that activin A decreases LEC motility. This
effect appears to be cell type–specific, as activin A increases
migration in most cell types tested, e.g., mast cell (Funaba
et al., 2003), epithelial cells (Dignass et al., 2002), and smooth
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Figure 2. Protein and gene expression profiles of melanomas transduced with the indicated transgenes. After intradermal injection of A375 cells overexpressing
the indicated genes, arising tumors were excised at day 22 and tested for the expression of transgenes by immunohistochemistry (a) and real-time PCR (b). (a) Cell
lines used are indicated in the top row; respective primary antibodies are shown at the left border; antibody binding is visualized by red color, and counterstaining
with hematoxylin is blue. Images in the right row are isotype controls. Bar ¼ 100mm (for anti-vimentin stains 500mm). (b) mRNA expression determined by real-
time PCR. Of note, INHBA does not reduce VEGF-C expression; mean±SD; *Po0.05; n¼ 5 per group. FST, follistatin; INHBA, inhibin bA subunit; VEGF, vascular
endothelial growth factor.
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muscle cells (Riedy et al., 1999). In addition, in our
experiments, activin A increased the migration of melanoma
cells in vitro, and this also holds true for other malignant cell
types, such as, e.g., prostate carcinoma (Kang et al., 2009).
Activin A induced SMAD2 phosphorylation in melanoma,
as well as in human and mouse lymphatic endothelium,
which was inhibited by FST, demonstrating that activin A
targets the same receptor complex in these cell types. To
reconcile cell type–specific effects of activin A–induced
migration of melanoma cells and reduced sprout formation
of LEC—one may postulate differences in co-receptor expres-
sion or usage in the respective cell type (Lin et al., 2006). An
example is endoglin; it is strongly expressed in the
endothelium and supports angiogenesis (Liu et al., 2014),
but—when expressed in cancer—it suppresses invasion and
metastasis (Henry et al., 2011). These effects are opposing to
those seen in our experiments with activin A. Of note,
endoglin interacts not only with ActRII but also with the
TGF-b type II receptor (Barbara et al., 1999). Endothelial cells
lacking endoglin do not grow because TGF-b/ALK1 signaling
is reduced and TGF-b/ALK5 signaling is increased (Lebrin
et al., 2004). Thus, as a possible explanation for our results,
activin A may recruit endoglin to ActRII, thereby dampening
TGF-b/ALK1 signaling in the endothelium. In our melanoma
cells, endoglin is poorly expressed, and thus this pathway may
not be active. The situation is complicated by our finding that
Wnt3a and TGF-b also phosphoylated SMAD2, albeit their
effects on migration were small. This further supports the
assumption that co-receptor usage determines the effect on
migration.
When analyzing activin A effects, one has to consider FST
expression. FST, the functional antagonist of activin A, pre-
vents activin A–induced SMAD2 phosphorylation. Quantifying
activin A/FST ratios in melanocytic lesions revealed significant
upregulation of activin A/FST ratios in primary melanoma as
compared with nevi and metastasis. On the first glance, this
appears as a paradox, because this would prevent lymphan-
giogenesis in primary lesions. However, our experiments
demonstrate that the lymphangiogenic capacity of melanoma
is mainly determined by VEGF-C, because (i) FST-overexpres-
sing A375 cells do not show enhanced lymphangiogenesis
compared with controls and (ii) FST does not revert Wnt1
effects, and it does not increase lymphangiogenesis in Wnt1-
overexpressing melanoma. Moreover, even though activin A
reduces the numbers of lymphatic vessels, INHBA melanoma
cells reach sentinel nodes with an equal efficacy and even
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faster than control tumors, which suggest that an elevated
activin A/FST ratio is a criterion for malignancy.
In conclusion, the first aspect of our study is that activin A is
an, to our knowledge previously unreported, anti-lymphangio-
genic molecule. Activin A inhibits lymphangiogenesis in vitro
and in vivo, but it appears not suitable for the treatment of
melanoma to reduce lymphangiogenesis, because it produces
a paradox situation: Even though lymphatic vessels are
significantly reduced, INHBA tumors entered lymphatic ves-
sels with high efficiency and, as a result, metastasized equally
well to control tumors. This observation provides additional
evidence for a critical finding that lymphangiogenesis and
tumorigenesis can be dissociated, supporting the concept
raised by Krneta et al. (2006) that tumor metastasis may not
be dependent on increased lymphangiogenesis as long as a
minimal intratumoral vessel density is maintained. The second
aspect covers the finding that primary human mela-
nomas express elevated activin A/FST ratios compared with
nevi and metastasis. Further studies are required, if this could
be used as a prognostic marker for the likelihood of sentinel
node metastasis.
MATERIALS AND METHODS
Cell lines
The human melanoma cell lines A375 (ATCC, Wesel, Germany), VM-1,
VM-30, and VM-34 (provided by W. Berger, Medical University
Vienna (Pirker et al., 2003)) were cultured in DMEM (Invitrogen,
Paisley, UK) supplemented with 10% fetal calf serum, 2 mM L-
glutamine, and 50 U ml 1 streptomycin/penicillin (Invitrogen). LECs
were isolated from human foreskin and separated by magnetic sorting
(Gro¨ger et al., 2007). To extend their life span, they were lentivirally
infected with the human telomerase gene (hTERT). Immortalized LECs
(LecTert) were cultivated in EBM-2 (endothelial cell basal medium-2,
Clonetics, Lonza, Basel, Switzerland) supplemented with 10% fetal
calf serum and EGM-2MV Single Quots supplement mix (Clonetics).
Antibodies and reagents
Goat anti-mouse Wnt1, rabbit anti-human INHBA, and goat anti-
human VEGF-C antibodies were from R&D Systems (Minneapolis,
MN); mouse anti-human FST was from Abcam (Cambridge, UK);
rabbit anti-human Phospho-Smad2 was from Cell Signal (Cell
Signaling Technology, Danvers, MA); rabbit anti-mouse Lyve-1 was
from Acris (Herford, Germany); rabbit anti-mosue CD31 was from
Neomarkers (Fremont, CA); mouse anti-human vimentin (clone V9)
was from Dako (Glostrup, Denmark); biotinylated secondary anti-
bodies were from Vector Laboratories (Burlingame, CA); horseradish
peroxidase rabbit anti-goat IgG was from Zymax (Novex, Life
Technologies, Carlsbad, CA); human recombinant TGFb was from
PeproTech (Rocky Hill, NJ); and human recombinant Wnt3a and
(activin A) ActA were from R&D Systems.
Retroviral transduction
Phoenix cells (provided by H. Stockinger, Medical University of
Vienna) were transduced with retroviral plasmid pLNCX and pLNCX/
Wnt1 (gift of A. McMahan, Harvard University), which has a
Geneticin resistance gene and/or with pBMN-I-GFP, pBMN-I-GFP/
FST (Grusch et al., 2006), or pBMN-I-GFP/VEGF-C (gift of M. Detmar,
Institute of Pharmaceutical Sciences, Zurich) using calcium phosphate
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precipitation to generate the retrovirus. A375 cells were infected with
virus-containing supernatants and selected by the respective markers.
INHBA was overexpressed using lentiviral particles (PLOHS_
100005788 from ThermoScientific, Waltham, MA), and cells were
selected using 5mg ml 1 blasticidin (Sigma, St Louis, MO).
Severe combined immunodeficient mouse model
All animal procedures were approved by the Animal Care and Use
Committee of the Medical University of Vienna. This xenograft model
was described previously (Loewe et al., 2006). Briefly, 2 106 A375
cells were injected intradermally into the right flank of 6-week-old
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Figure 5. Activin A increases melanoma migration in vitro. (a) A375 cells overexpressing the indicated genes were seeded in 96-well plates (2,000 cells per well),
and proliferation was determined using the EZ4U kit, n¼ 6 per group. (b) In vitro wound healing assay of indicated melanoma cells, representative example of
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female hairless severe combined immunodeficient mice (Crl:SHO-
PrkdcscidHrhr; Charles River Laboratories, Wilmington, MA). Using a
caliper, the tumors were measured and the volume was calculated
using the formula V¼ (p/6) (length) (width)2. Tumors were
excised at day 22 and wounds were sutured. The tumors were
divided in two parts: one part was fixed in 4% formaldehyde for
paraffin embedding and the other part was transferred into RNAlater
(Ambion, Life Technologies) for RNA isolation. Animals were then
continuously monitored for palpable metastasis in the right axilla. In
case of palpable nodules, animals were killed and lymph nodes were
harvested and processed as described for the primary tumors.
Immunohistochemistry
Following de-paraffinization and incubation in citrate buffer (Dako),
sections were incubated with primary and appropriate biotinylated
secondary antibodies. Bound antibodies were visualized using the
horseradish peroxidase–conjugated Streptavidin kit (Novocastra,
Leica Biosystems, Nussloch, Germany). Sections were counterstained
with hematoxylin.
For quantification of CD31þ and Lyve-1þ vessels, sections were
digitalized using the ScanScope CS2 (Aperio Technologies, Vista, CA)
and positive vessels were counted in a surrounding zone of 250mm
around the tumor by an investigator blinded to the experimental
group (as exemplified in Figure 3).
For the tissue arrays, human samples from human compound nevi
(n¼ 19), T2 primary melanoma (n¼ 10; SSM, T2a, thickness
1–2 mm), and melanoma metastasis (n¼ 81) were used. Punch
biopsies (diameter 0.5 mm) were taken from the paraffin blocks by
parallel viewing of hematoxylin and eosin-stained sections (from the
dermatopathological data bank; according to ethics committee
permission 405/2006 and extension 180/11/2013 and written,
informed consent). For the production of tissue arrays, punches
were inserted into a new paraffin block, cut into 5-mm sections,
deparaffinized, and stained as described above. Staining intensities
were determined in digitalized images where the blue and green
colors were subtracted from the image using Adobe Photoshop CS4
(Adobe, San Jose, CA). The remaining red pixel image was converted
into a binary image in which the pixels were quantified using
the histogram analysis and the listing of pixels in ImageJ, developed
by Wayne Rasband (retired from NIH); data are analyzed by IBM
SPSS Statistics 21 (IBM, Armonk, NY) and presented as box blots
(http://en.wikipedia.org/wiki/Box_plot).
Real-time PCR
RNA was isolated from tumors using the RNeasy Mini Kit (Qiagen,
Hilden, Germany), and was reverse transcribed using the Revert Aid
H First Strand cDNA synthesis kit (Fermentas, Life Technologies) and
random hexamer primers. Real-time PCR primers (FAM primers) were
obtained from Applied Biosystems (Foster City, CA), Assays-on-
demand. Reaction mixtures contained 1ml of complementary DNA,
12.5ml of TaqMan Universal PCR Master Mix (Applied Biosystems),
and 1.25ml Assay-on-demand into a total volume of 25ml. Cycling
parameters were as follows: 50 1C for 2 minutes, 95 1C for 10 minutes,
followed by 40 cycles at 95 1C for 10 seconds and 60 1C for 1 minute.
Housekeeping genes were glyceraldehyde-3-phosphate dehydrogen-
ase for human primers and b-2 microglobulin for mouse primers.
Reactions were run on StepOnePlus RT-PCR, and data analysis was
performed with the StepOnePlus Software v2.0 (Applied Biosystems).
mRNA concentrations were calculated by subtracting CT of the
housekeeping gene from CT of the target gene (D). The mean of D
control was subtracted from the D target gene reaction (DDCT) and
calculated as 2(DDCT).
Western blot
A375 cells or LecTert were exposed for 30 minutes to serum-free
supernatants of A375 cells overexpressing the indicated genes. Cells
were then lysed in radio-immunoprecipitation assay buffer, and 20-mg
protein lysates were loaded onto SDS gels, electrophoresed, and
blotted. Membranes were blocked in 5% skim milk (Fluka, Buchs,
Germany) followed by incubation with primary and secondary
antibodies; bound antibodies were visualized by chemiluminescence
(enhanced chemiluminescence plus, Amersham, GE Healthcare,
Little Chalfont, UK) and exposure to hyperfilm enhanced
chemiluminescence.
12,000
10,000
8,000
6,000
4,000
2,000
0
*
*
*
*
*
Control
Control
Wnt1
FST
Wnt1/FST
INHBA
INHBA
VEGF-C
Neg. control
Sp
ro
ut
 le
ng
th
 (μ
m
)
Figure 6. Activin A decreases lymphatic sprout formation in vitro. In vitro spheroid sprouting assay of lymphatic endothelial cells; summary of three independent
experiments with n¼ 10 per group. VEGF-C was used as a positive control. Fresh medium without the addition of growth factors served as a negative (Neg.)
control; mean±SD; *Po0.05. Inserted images are examples of spheroids stimulated with supernatants of control or INHBA A375 cells. INHBA, inhibin bA
subunit; VEGF, vascular endothelial growth factor.
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Proliferation, migration, and spheroid sprouting assays
Cell proliferation was determined with the EZ4U (Biomedica, Vienna,
Austria) or the Picogreen (Life Technologies) kit. Cell numbers were
calculated by using a standard curve. For the migration assay, the
IncuCyte ZOOM (Essen BioScience, Ann Arbor, MI) was used. A375
cells were seeded into an ImageLock plate and the confluent cell
monolayer was wounded using the 96-well WoundMaker. The plate
was then placed in the IncuCyte ZOOM and pictures were taken
every hour for 56 hours. Quantification was performed by measuring
the number of cells that migrated into wounds.
For sprouting assays, spheroids of LecTert cells were produced as
described (Korff and Augustin, 1999; Niederleithner et al., 2012),
embedded into collagen/methocel gels, and incubated with
serum-free supernatants from A375 cells overexpressing indicated
genes (collected after 48 hours) supplemented with fresh fetal
calf serum (0.5%). The negative control was fresh medium plus
0.5% fetal calf serum and the positive control was supernatant from
VEGF-C-overexpressing A375 cells. Pictures were taken 6 hours later,
and numbers and lengths of sprouts were counted blinded to
conditions. The cumulative sprout length was calculated by
multiplying numbers length of sprouts in 10 spheroids per
condition.
Statistical analysis
All experiments were performed in triplicate and repeated at least
twice. Data are expressed as mean±SD; significance was assessed by
analysis of variance followed by Tukey’s honestly significant differ-
ence test.
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